Search Within

Melanie Ann Hullings

Formats
  1. Meeting Abstract (15)
  2. Journal Article (4)
  3. Guidelines (1)
Groups
  1. Department of Medicine (20)
  2. Genitourinary Oncology Service (20)
  3. Solid Tumor Oncology Division (20)
  4. GSK Faculty (11)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (8)
  6. Hematologic Malignancies, Division of (7)

More Groups

People
  1. Howard Scher (20)
  2. Emily Carbone (10)
  3. Ethan Barnett (7)
  4. Michael Morris (7)
  5. Susan Slovin (7)
  6. Dana Rathkopf (6)

More People

Years
  1. 2020 (4)
  2. 2019 (4)
  3. 2018 (6)
  4. 2016 (3)
  5. 2014 (1)
  6. 2013 (2)
Publications
  1. Journal of Clinical Oncology (12)
  2. Annals of Oncology (2)
  3. Cancer Research (2)
  4. Clinical Cancer Research (1)
  5. Clinical Pharmacology & Therapeutics (1)
  6. European Urology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (12)
  2. American Association for Cancer Research (3)
  3. Oxford University Press (2)
  4. American Medical Association (1)
  5. Elsevier Science, Inc. (1)
  6. Nature Publishing Group (1)

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Autio, K. A.; Antonarakis, E. S.; Cheng, H. H.; Arauz, G.; Slack, A.; Hullings, M.; Scher, H. I.; Feng, F. Y.; Knudsen, K. E.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Microsatellite instability in prostate cancer and response to immune checkpoint blockade
    Meeting Abstract

    Abida, W.; Cheng, M. L.; Armenia, J.; Middha, S.; Autio, K. A.; Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Carbone, E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Graf, R. P.; Hulling, M.; Carbone, E.; Dittamore, R.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems
    Meeting Abstract

    Hornberger, J.; Graf, R. P.; Hulling, M.; Attard, G.; Allan, A.; Dittamore, R.; Scher, H. I.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Carbone, E.; Showunmi, A.; Hullings, M.; Morris, M. J.; Autio, K. A.; Kampel, L. J.; Molina, A. M.; Chen, Y.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A Phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Slovin, S. F.; Autio, K. A.; Delacruz, A.; Shelkey, G.; Pisano, K.; Hullings, M.; DeNunzio, M.; Morris, M. J.; Scher, H. I.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naive patients with progressive metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Danila, D. C.; Kuzel, T.; Cetnar, J. P.; Rathkopf, D. E.; Morris, M. J.; Alumkal, J. J.; Butler, A.; Curley, T.; Hullings, M.; Buddle, J. R.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer
    Meeting Abstract

    Touijer, K. A.; Carver, B. S.; Coleman, J. A.; Laudone, V. P.; Hullings, M.; Ehrlich, S. S.; DeNunzio, M.; Reuter, V. E.; Eastham, J. A.; Danila, D. C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Sadelain, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Riviere, I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save